In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

  • D. J. BiedenbachEmail author
  • S. K. Bouchillon
  • B. Johnson
  • J. Alder
  • D. F. Sahm
Original Article


Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The activity of tedizolid against S. aureus was potent and consistent in Latin America (MIC90, 0.5 mg/L), Australia and New Zealand (MIC90, 0.25 mg/L), and China (MIC90, 0.5 mg/L). Based on MIC90 results, tedizolid was four- to eight-fold more active than linezolid against S. aureus, including both methicillin-susceptible and -resistant isolates. Only two tedizolid non-susceptible strains were observed; both had intermediate minimum inhibitory concentration (MIC) values of 1 mg/L, for which the MICs of linezolid was higher (≥2 mg/L). Tedizolid (MIC90, 0.25 mg/L) was four-fold more potent than linezolid (MIC90, 1 mg/L) against S. pneumoniae in all countries that provided isolates. The findings from this study support the global clinical development of tedizolid for Gram-positive infections.


Minimum Inhibitory Concentration Linezolid Teicoplanin Daptomycin Oxazolidinones 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Thomas Lynch and Aubrey Smith for their support in the protocol design, data analysis, and development of this manuscript.

Compliance with ethical standards


This work was supported by Bayer HealthCare Pharmaceuticals.

Conflict of interest

DJB, SKB, BJ, and DFS are employees of International Health Management Associates, Inc. None of the IHMA authors have personal financial interests and have none to declare. JA is an employee of Bayer HealthCare Pharmaceuticals.

Ethical approval

These data have not been presented in any other format or other journals and comply with the ethical standards of the journal. This was an in vitro study only and did not include patients or animals; therefore, informed consent was not needed.


  1. 1.
    Popovich KJ, Weinstein RA, Hota B (2008) Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 46:787–794CrossRefPubMedGoogle Scholar
  2. 2.
    Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW, Baxter MR, Hoban DJ, Karlowsky JA, Zhanel GG (2015) Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13. J Antimicrob Chemother 70:2199–2202CrossRefPubMedGoogle Scholar
  3. 3.
    Hall RG 2nd, Michaels HN (2015) Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Infect Drug Resist 8:75–82CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moellering RC Jr (2014) Tedizolid: a novel oxazolidinone for Gram-positive infections. Clin Infect Dis 58(Suppl 1):S1–S3CrossRefPubMedGoogle Scholar
  5. 5.
    Rybak JM, Roberts K (2015) Tedizolid phosphate: a next-generation Oxazolidinone. Infect Dis Ther [Epub ahead of print]Google Scholar
  6. 6.
    Barber KE, Smith JR, Raut A, Rybak MJ (2016) Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother 71:152–155CrossRefPubMedGoogle Scholar
  7. 7.
    Kanafani ZA, Corey GR (2012) Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 21:515–522CrossRefPubMedGoogle Scholar
  8. 8.
    Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Goering RV, Jenkins SG, Shaw KJ (2014) Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center. Antimicrob Agents Chemother 58:6949–6952CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Rodríguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ (2012) In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 67:167–169CrossRefPubMedGoogle Scholar
  10. 10.
    Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA (2015) Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 75:253–270CrossRefPubMedGoogle Scholar
  11. 11.
    Chen KH, Huang YT, Liao CH, Sheng WH, Hsueh PR (2015) In vitro activities of tedizolid and linezolid against gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother 59:6262–6265CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee Y, Hong SK, Choi S, Im W, Yong D, Lee K (2015) In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study. Ann Lab Med 35:523–530CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF (2015) Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81:112–118CrossRefPubMedGoogle Scholar
  14. 14.
    Burdette SD, Trotman R (2015) Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 61:1315–1321CrossRefPubMedGoogle Scholar
  15. 15.
    Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P (2014) Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis 58(Suppl 1):S51–S57CrossRefPubMedGoogle Scholar
  16. 16.
    Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705CrossRefPubMedGoogle Scholar
  17. 17.
    Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P (2015) Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 59:864–871CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—10th edn. CLSI document M07-A10. CLSI, WayneGoogle Scholar
  19. 19.
    Clinical and Laboratory Standards Institute (CLSI) (2015) Performance standards for antimicrobial susceptibility testing; Twenty-sixth informational supplement. CLSI document M100-S26. CLSI, Wayne, PAGoogle Scholar
  20. 20.
    Thomson KS, Goering RV (2013) Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother 57:2892–2895CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wang Y, Li D, Song L, Liu Y, He T, Liu H, Wu C, Schwarz S, Shen J (2013) First report of the multiresistance gene cfr in Streptococcus suis. Antimicrob Agents Chemother 57:4061–4063CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • D. J. Biedenbach
    • 1
    Email author
  • S. K. Bouchillon
    • 1
  • B. Johnson
    • 1
  • J. Alder
    • 2
  • D. F. Sahm
    • 1
  1. 1.International Health Management Associates, Inc.SchaumburgUSA
  2. 2.Bayer HealthCare PharmaceuticalsWhippanyUSA

Personalised recommendations